This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Penumbra (PEN) Gains on New Launches Amid Currency Headwind
by Zacks Equity Research
Penumbra's (PEN) ability to improve net gross margins and EPS amid ongoing inflationary pressure and supply-chain headwinds buoy optimism.
Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover
by Zacks Equity Research
If this rule is finalized without any changes to reimbursement practices, Myomo's (MYO) MyoPro could be reimbursed in a lump-sum manner by CMS.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Revenue growth across global product categories and a broad geographic footprint bode well for Teleflex (TFX).
Teleflex's (TFX) Urolift Global Expansion Aids Amid Cost Woes
by Zacks Equity Research
Teleflex's (TFX) vascular and interventional access product portfolios witness accelerated growth following the $976-million acquisition of Vascular Solutions.
Labcorp (LH) Announces Completion of the Fortrea Spin-off
by Zacks Equity Research
Labcorp (LH) completes the planned spin-off of Fortrea to operate as an independent clinical development business.
Canopy Growth (CGC) Improves Liquidity With Another Selloff
by Zacks Equity Research
Canopy Growth's (CGC) decision to divest facilities aligns with its organizational transformation plan.
Here's Why You Should Retain Zimmer Biomet (ZBH) for Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) due to the continued procedure recovery and the strength of emerging markets.
Bruker (BRKR) Launches the SciY Platform of Software Solutions
by Zacks Equity Research
Bruker's (BRKR) SciY platform provides many digital end-to-end solutions for life science research and development, manufacturing automation and QC.
Myriad Genetics (MYGN) Test Volume Rises Amid Margin Woe
by Zacks Equity Research
Myriad Genetics' (MYGN) collaboration with medical imaging provider, SimonMeD, is expected to advance precision medicine with a new hereditary cancer assessment program.
Abbott (ABT) Teams Up With the ADA to Evaluate CGM Systems
by Zacks Equity Research
Abbott (ABT) and ADA are going to offer personalized, therapeutic nutrition for diabetes people using CGM systems.
BioSig (BSGM) Inks New Deal to Advance AI in Electrophysiology
by Zacks Equity Research
The foundation of BioSig's (BSGM) AI medical device platform is set to be built upon integrated healthcare datasets.
OrthoPediatrics (KIDS) Unveils GIRO for Pediatric Orthopedics
by Zacks Equity Research
The GIRO Growth Modulation System by OrthoPediatrics (KIDS) introduces a tether device designed specifically for pediatric patients.
Integra (IART) Completes Enrollment in the DuraSorb IDE Study
by Zacks Equity Research
Integra (IART) announces the completion of patient enrollment in the DuraSorb IDE clinical study.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) due to the performance of its oncology business and product launches.
Bruker (BRKR) Introduces the D6 PHASER Benchtop XRD Platform
by Zacks Equity Research
Bruker's (BRKR) new D6 PHASER platform is to be used for material analysis and advanced research.
Factors That Make HCA Healthcare (HCA) a Lucrative Bet Now
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on the resumption of elective surgeries, acquisitions and strong cash-generation abilities.
Abbott (ABT) EPD Sales Aid Growth Amid Currency Headwind
by Zacks Equity Research
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
Organigram (OGI) Grows in Cannabis Space With SHRED X Heavies
by Zacks Equity Research
Organigram's (OGI) SHRED X Heavies is not only the first infused pre-roll in the SHRED product portfolio but also joins a lineup of value-driven, convenient and bold-flavored offerings.
Syneos Health (SYNH) Collaborates With uMotif for New Platform
by Zacks Equity Research
Syneos Health (SYNH) partners with uMotif to deliver the patient-centric eClinical platform.
Zacks.com featured highlights Penumbra, Trip.com, Transportadora de Gas del Sur and Vipshop
by Zacks Equity Research
Penumbra, Trip.com, Transportadora de Gas del Sur and Vipshop have been highlighted in this Screen of The Week article.
Envista (NVST) Gains From New Acquisitions Amid FX Woes
by Zacks Equity Research
Envista's (NVST) implant businesses in Europe perform well on the back of disciplined commercial execution.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) due to the performance of its dental business.
Medtronic's (MDT) MiniMed 780G System Favored by New Data
by Zacks Equity Research
Medtronic (MDT) presents the clinical and real-world data on the MiniMed 780G system at ADA Scientific Sessions in San Diego.
Buy These 4 Low-Beta Stocks to Counter the Choppy Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Penumbra (PEN), Trip.com Group (TCOM), Transportadora (TGS) and Vipshop Holdings (VIPS) are poised to gain.
Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure
by Zacks Equity Research
Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.